When GLP-1 Isn't Right for You: What Your Doctor Might Recommend Instead

GLP-1 medications have dominated the weight loss conversation — but they're not the only option, and they're not the right option for everyone. Whether you've been denied GLP-1 therapy due to contraindications, can't tolerate the side effects, or simply can't afford it, other evidence-based treatments exist. Here's an honest look at each.

FDA-Approved Weight Loss Medications (Non-GLP-1)

Naltrexone-Bupropion (Contrave)

Contrave combines naltrexone (an opioid antagonist) with bupropion (an antidepressant). It works on the brain's reward pathways and appetite regulation centers. Average weight loss in clinical trials: approximately 5–8% of body weight.

Best for: Patients who can't take GLP-1s and also have issues with cravings, emotional eating, or depression. The bupropion component can address mood symptoms simultaneously.

Limitations: Cannot be used by patients with seizure disorders, eating disorders (bulimia/anorexia), or who are taking opioid medications. Less effective than GLP-1s on average.

Phentermine (Adipex, Lomaira)

A sympathomimetic amine that suppresses appetite through central nervous system stimulation. It's one of the oldest weight loss medications still in use and is FDA-approved for short-term use (up to 12 weeks).

Best for: Short-term kickstart, especially when combined with lifestyle changes. Affordable and widely available.

Limitations: Only approved for short-term use. Can increase blood pressure and heart rate. Not appropriate for patients with cardiovascular disease. Potential for dependence (it's a Schedule IV controlled substance).

Orlistat (Xenical, Alli)

Works in the gut by blocking fat absorption — about 30% of dietary fat passes through unabsorbed. Available over-the-counter (Alli) and by prescription (Xenical). Average weight loss: 3–5% of body weight.

Best for: Patients who want a non-systemic medication (it doesn't enter the bloodstream significantly).

Limitations: GI side effects (oily stools, fecal urgency, flatulence) are common and can be socially distressing. Modest weight loss compared to GLP-1s.

Off-Label Medications

Metformin

Primarily a diabetes medication, but increasingly prescribed off-label for weight management. Produces modest weight loss (3–5%) and improves insulin sensitivity. Affordable as a generic and well-studied for long-term safety.

Best for: Patients with pre-diabetes or insulin resistance who don't qualify for or can't access GLP-1s. Often used as a "bridge" or complement to lifestyle changes.

Topiramate (Topamax)

An anti-seizure medication that suppresses appetite as a side effect. Sometimes combined with phentermine (brand name: Qsymia). Can produce meaningful weight loss but has significant side effects including cognitive dulling, tingling, and kidney stones.

Bariatric Surgery

For patients with severe obesity (BMI ≥40, or ≥35 with comorbidities), bariatric surgery remains the most effective long-term weight loss intervention. Modern procedures — gastric sleeve, gastric bypass, and duodenal switch — produce average weight loss of 20–35% of total body weight and often resolve type 2 diabetes, sleep apnea, and hypertension.

Best for: Patients with severe obesity who haven't achieved sufficient results with medication therapy, or who have obesity-related conditions requiring more aggressive intervention.

Limitations: Surgical risks, permanent anatomical changes, lifetime nutritional supplementation requirements, and the need for ongoing follow-up care.

Intensive Lifestyle Interventions

Structured lifestyle programs — combining calorie-controlled diets, regular exercise, and behavioral counseling — produce average weight loss of 5–10% when patients are highly adherent. Programs like the Diabetes Prevention Program (DPP) have strong evidence bases and are covered by many insurance plans and Medicare.

Best for: Patients with BMI 25–30 who may not qualify for medications, patients who want to try lifestyle changes before pharmacotherapy, or patients using medication who want to maximize their results.

Emerging Alternatives

The GLP-1 class is expanding rapidly. Retatrutide (a triple-hormone agonist targeting GLP-1, GIP, and glucagon receptors) has shown even greater weight loss than tirzepatide in early trials and may offer options for patients who don't respond to current GLP-1s. Oral GLP-1 formulations are also becoming more available, potentially addressing needle-phobic patients who previously avoided treatment.

The Honest Conversation

If GLP-1 medication isn't right for you right now, that doesn't mean weight management treatment isn't available. The alternatives are less dramatic in their results — none match GLP-1s' average weight loss — but "less dramatic" isn't "ineffective." A 5–8% weight loss through Contrave or metformin still produces measurable improvements in blood sugar, blood pressure, and cardiovascular risk.

The worst option is no treatment at all. If GLP-1s are off the table, work with your provider to find the next-best approach for your specific situation.